Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
national blog main
san francisco blog main
53
×
startups
53
×
life sciences
national top stories
san francisco top stories
biotech
boston blog main
new york blog main
deals
boston top stories
san diego blog main
new york top stories
san diego top stories
raleigh-durham blog main
wisconsin blog main
detroit blog main
seattle blog main
detroit top stories
fda
wisconsin top stories
boulder/denver blog main
texas blog main
indiana blog main
national
raleigh-durham top stories
texas top stories
seattle top stories
boulder/denver top stories
cancer
clinical trials
indiana top stories
vc
investing
san francisco
software
cancer immunotherapy
eli lilly
pfizer
venture capital
What
bio
roundup
drug
new
drugs
medicines
startup
million
biotech
companies
cancer
medical
today
ceo
company
deal
developing
health
healthcare
life
science
therapeutics
therapy
week
available
based
crispr
develop
diabetes
disease
gene
ipo
lands
san
technology
years
acquisitions
alzheimer’s
announced
big
Language
unset
unknown
Current search:
startups
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
5 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome
@xconomy.com
5 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Review: Inside the House of Lies at Theranos
@xconomy.com
5 years ago
Invitae Offers $55M for Singular Bio to Expand Prenatal Test Business
@xconomy.com
5 years ago
With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes
@xconomy.com
5 years ago
HAP Partners With Livongo on Tech-Enabled Diabetes Compliance Program
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Rani’s “Robotic Pill” for Biologics Clears First Hurdle in Humans
@xconomy.com
5 years ago
Rani’s “Robotic Pill” for Biologics Clears First Hurdle in Humans
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
After 33 Exits in 5 Years, WI Seeks “More and Bigger” Startup Deals
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
From Immigration to Taxes, Execs Talk Trump Effect on Innovation
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
ResMed Boosts Connected Health Play With $225M Propeller Health Deal
@xconomy.com
5 years ago
Auris Health Lands $220M to Expand Sales of Lung Testing Medical Robot
@xconomy.com
5 years ago
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push
@xconomy.com
5 years ago
Andreessen Leads $300M Bet on Devoted Health’s Senior Care Approach
@xconomy.com
6 years ago
In Boston’s Shadow, Rhode Island Fights for Life Science Jobs, Respect
@xconomy.com
6 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care
@xconomy.com
6 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
6 years ago
Verana Health Lands $30M Financing Led By GV, Adds Miki Kapoor as CEO
@xconomy.com
6 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com
6 years ago
Virtual Physical Therapy Firms Reflexion and MindMaze Probe Markets
@xconomy.com
6 years ago
Quest Analytics Buys Healthcare Compliance Software Firm BetterDoctor
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
First
Prev
Page 1
(current)
Next
Last